Thymine test for 5-fluorouracil side effects
Not Applicable
Completed
- Conditions
- Gastrointestinal cancersCancer - Bowel - Back passage (rectum) or large bowel (colon)Cancer - Bowel - Small bowel (duodenum and ileum)Cancer - Breast
- Registration Number
- ACTRN12615000586516
- Lead Sponsor
- The University of Auckland
- Brief Summary
The test appears to be able to distinguish patiients at risk of 5-FU related GI toxicity. A prospective study to confirm these findings is ongoing
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 37
Inclusion Criteria
Patients diagnosed with histologically confirmed gastrointestinal cancers or metastatic breast cancer; about to start or have commenced therapy with single agent 5FU or capecitabine
Exclusion Criteria
Pregnant or breast feeding; concurrent adbominopelvic radiation therapy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine whether the ratio of thymine to metabolites detected in the urine sample after the thymine test dose can discriminate between patients who tolerate 5-FU/capecitabine treatment and those who experience severe toxicity.[6 months]
- Secondary Outcome Measures
Name Time Method SNP variants of genes associated with abberrant 5-FU disposition, such as didhydropyrimidine dehydrogenase, will be assessed to detemine if any of these correlate with inter-individual differences in the thymine ratio detected in urine[6 months]